October 3, 2025Open Access

Supplementary Figure 8 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Analysis reveals that SPP1+ TAMs contribute to poor prognosis in ccRCC by promoting CD8+ T-cell dysfunction.

SPP1+ TAMs correlate with poor prognosis in patients with ccRCC, highlighting their role in promoting disease severity.
Inhibition of CD8+ T-cell function by SPP1+ TAMs suggests a mechanism behind immunotherapy resistance in renal cell carcinoma.
The study implies that targeting SPP1+ TAMs could improve treatment outcomes for ccRCC patients undergoing immunotherapy.
Further investigation is needed to validate the prognostic value of SPP1+ TAMs in broader patient cohorts.

Jiang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark